Cargando…
Effects of Evolocumab on Cardiovascular Events
BACKGROUND: Evolocumab is a potent lipid-lowering drug that decreases plasma levels of low-density lipoprotein cholesterol (LDL-C) by 50-60%. FOURIER is a landmark randomized trial involving 27,564 patients with established cardiovascular disease already on statins and plasma LDL-C levels > 70 mg...
| Autor principal: | |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Bentham Science Publishers
2017
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5730965/ https://www.ncbi.nlm.nih.gov/pubmed/28925859 http://dx.doi.org/10.2174/1573403X13666170918165713 |